Formulary Updates – May 2018
Posted on May 9, 2018
Health New England’s 2018 formularies are available on healthnewengland.org. We encourage Providers to utilize the online formularies, which are accessible to all users without a login or password.
The online formularies are updated throughout the year as changes are made. We have three formularies, one for each line of business – Commercial, Medicare Advantage and BeHealthy Partnership/Medicaid. Each formulary includes the tier assignment for each drug and any drug-specific medication management requirements, including quantity limitations, step therapy requirements and prior authorization requirements. For your convenience, when searching our Commercial and Medicaid formularies, you will find we have linked both clinical criteria and prior authorization forms.
Most recently the following medications have been reviewed:
| Brand Name: Fiasp | Generic Name: Insulin aspart |
| Brand Name: Gocovri | Generic Name: Amantadine |
| Brand Name: Idhifa | Generic Name: Enasidenib |
| Brand Name: Mayret | Generic Name: Glecaprevir and pibrentavir |
| Brand Name: Nerlynx | Generic Name: Neratinib |
| Brand Name: Nityr | Generic Name: Nitisnone |
| Brand Name: Soliqua | Generic Name: Insulin glargine and lixisenatide |
| Brand Name: Vosevi | Generic Name: Sofosbuvir, velpatasvir, voxilaprevir |
| Brand Name: Xultophy | Generic Name: Insulin degludec and liraglutide |
